Telisotuzumab (powder)

Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers[1].

Product Specifications

CAS Number

[1781223-80-0]

Product Name Alternative

ABT-700 (powder)

UNSPSC

12352203

Target

Apoptosis; c-Met/HGFR

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

[Telisotuzumab(powder)]

Molecular Weight

(146.1 kDa)

References & Citations

[1]Jieyi Wang, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016 Feb 16;16:105.